Trials & Filings

Viatris’ Effexor Approved in Japan for Generalized Anxiety Disorder

Effexor becomes the first approved treatment option in Japan for GAD.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Viatris

Viatris Inc., a global healthcare company, received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for Effexor SR 37.5 mg / 75 mg capsules (venlafaxine hydrochloride), a serotonin-noradrenaline reuptake inhibitor for the treatment of adults with generalized anxiety disorder (GAD). With the MHLW’s decision, Effexor becomes the first approved treatment option in Japan for GAD. Effexor is currently approved in Japan for the indication of major depressive disorder in...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters